Skip to main content

Weather alert

Due to Hurricane Isaias, our Patient Service Centers in affected areas may be closed. We ask that patients please double check your appointment status to ensure your designated Patient Service Center is operational. For site-specific information, please use Find a location and enter your zip code.

Hide

AccuType® CP: Importance of Genotyping

AccuType CP conveniently identifies the genetic mutation of the CYP2C19 genotypes (*2,*3,*4,*5) that cause clopidogrel resistance, and determines if a patient should be prescribed clopidogrel. It reports if patients are a poor, intermediate or extensive metabolizer of the drug clopidogrel:

Metabolizer TypesClinical Interpretation
Hyperextensive - HMIncreased bleeding risk
Extensive - EMStandard clopidogrel dose recommended
Intermediate - IMIncrease clopidogrel dose or consider alternate therapy
Poor - PM

Our genetic counselors can provide additional assistance with AccuType CP results interpretation. Call 1-866-GENE-INFO (1-866-436-3463).

References

  1. Gladding P, et al. Pharmacogenetics Testing for Clopidogrel Using the Rapid INFINITI Analyzer, Journal of the American College of Cardiology: Cardiovascular Interventions 2009; 2:1095-1101.
  2. Mega et al. Cytochrome P-450 Polymorphisms and Response to Clopidogrel, New England Journal of Medicine 2009; 22; 360 (4): 354-362.
  3. Simon T, et al. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. New England Journal of Medicine 2009; 360 (4): 363-375.
  4. Hulot et al, Cardiovascular Risk in Clopidogrel Treated Patients According to Cytochrome P450 2C19*2. Loss of Function Allele or Proton Pump Inhibitor Co-administration: A Systematic Meta-Analysis JACC 2010. 56(2) 134-143.
  5. Mega et al, Reduced Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients treated with Clopidogrel Predominantly for PCI: A Meta-Analysis. JAME 2010; 304 (16) 1821- 1830.